Victory Capital Management Inc. grew its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 17.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,060 shares of the biotechnology company’s stock after purchasing an additional 608 shares during the period. Victory Capital Management Inc.’s holdings in Anika Therapeutics were worth $200,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ANIK. Thomson Horstmann & Bryant Inc. purchased a new stake in Anika Therapeutics during the second quarter worth about $11,345,000. Bank of New York Mellon Corp increased its holdings in Anika Therapeutics by 76.8% during the second quarter. Bank of New York Mellon Corp now owns 490,433 shares of the biotechnology company’s stock worth $24,199,000 after buying an additional 213,055 shares during the last quarter. Columbia Wanger Asset Management LLC purchased a new stake in Anika Therapeutics during the first quarter worth about $7,395,000. Wells Fargo & Company MN increased its holdings in Anika Therapeutics by 891.4% during the first quarter. Wells Fargo & Company MN now owns 166,674 shares of the biotechnology company’s stock worth $7,240,000 after buying an additional 149,862 shares during the last quarter. Finally, Stifel Financial Corp increased its holdings in Anika Therapeutics by 935.0% during the first quarter. Stifel Financial Corp now owns 140,704 shares of the biotechnology company’s stock worth $6,119,000 after buying an additional 127,109 shares during the last quarter. Institutional investors own 84.47% of the company’s stock.

A number of research firms recently issued reports on ANIK. Zacks Investment Research upgraded shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the company’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total value of $710,476.03. Following the completion of the transaction, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Charles H. Sherwood sold 63,799 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the completion of the transaction, the chief executive officer now owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The disclosure for this sale can be found here. Corporate insiders own 6.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Victory Capital Management Inc. Has $200,000 Stake in Anika Therapeutics Inc. (ANIK)” was reported by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/22/victory-capital-management-inc-has-200000-stake-in-anika-therapeutics-inc-anik.html.

Anika Therapeutics Inc. (NASDAQ ANIK) opened at 57.02 on Friday. Anika Therapeutics Inc. has a 12 month low of $41.38 and a 12 month high of $57.41. The firm’s 50-day moving average is $53.44 and its 200-day moving average is $47.83. The company has a market cap of $835.80 million, a price-to-earnings ratio of 25.33 and a beta of 1.65.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The firm had revenue of $33.50 million during the quarter, compared to analyst estimates of $27.20 million. During the same quarter in the prior year, the firm earned $0.57 EPS. The business’s revenue for the quarter was up 25.9% compared to the same quarter last year. On average, analysts anticipate that Anika Therapeutics Inc. will post $2.20 EPS for the current fiscal year.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.